156100.KQ L&K Biomed Ltd.
- Market cap
- KRW 130B
- P/E
- 50.7x
- P/B
- 2.03x
- ROE
- 49.9%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 156100.KQ undervalued?
Graham number156100.KQ trades 114.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
L&K Biomed Ltd. fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (49.9%), above 20%.
ROA 1/1
Return on assets (29.0%) is above the industry median (-9.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-249.2%) is below the industry median (-3.8%).
Revenue Growth 2/2
Revenue grew 25.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.8%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 11.0x against interest expense, well covered.
PE vs Market 0/1
PE (50.7x) is above the market median (11.3x).
PE vs Industry 0/1
PE (50.7x) is above the industry median (22.5x).
PBV 1/1
Price to book (2.0x) is below the industry median (3.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 103.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
L&K Biomed Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About L&K Biomed Ltd.
L&K Biomed Ltd., engages in the manufacturing, production, and sales of medical devices in South Korea, the United States, Thailand, and internationally. The company offers spinal products comprising BlueEX-T, BluEX-TC, BluEX-A, BlueEX-L, and BluEX-ATP; BluEX-LT, an advanced lateral cage system for spinal lordosis restoration; PathLoc-TM, an expandable TLIF/PLIF lumbar cage system; AccelFix-XL, an expandable lateral lumbar cage system; AccelFix-XTP, an expandable lumbar cage…
Full company profileL&K Biomed Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
L&K Biomed Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 19.8B | 29.9B | 36.1B | 38.9B | 42.5B |
| Gross Profit | 14.9B | 25.8B | 30.2B | 32.2B | 36.0B |
| Operating Income | -14.0B | -6.49B | 3.08B | 715M | 2.76B |
| EBITDA | -11.8B | -2.15B | 15.1B | -11.3B | 38.6B |
| Net Income | -13.6B | -1.87B | 9.74B | -16.3B | 31.8B |
| EPS | -808 | -94 | 489 | -729 | 1,423 |
| Balance Sheet | |||||
| Total Assets | 52.7B | 62.8B | 83.1B | 83.5B | 110B |
| Total Liabilities | 41.9B | 32.2B | 47.0B | 44.8B | 53.1B |
| Shareholders' Equity | 12.3B | 35.4B | 42.5B | 45.5B | 63.7B |
| Cash & Short-term Investments | 7.39B | 5.05B | 3.83B | 3.18B | 4.64B |
| Cash Flow | |||||
| Operating Cash Flow | -6.88B | -1.37B | -7.43B | -13.9B | -2.43B |
| Capital Expenditure | 0.00 | 2.10B | 615M | 3.13B | 7.39B |
| Free Cash Flow | -6.88B | -3.47B | -8.05B | -17.0B | -9.81B |
| Ratios | |||||
| ROE | -111.1% | -5.3% | 22.9% | -35.8% | 49.9% |
| ROA | -25.9% | -3.0% | 11.7% | -19.5% | 29.0% |
| Net Profit Margin | -68.9% | -6.2% | 27.0% | -41.9% | 74.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
L&K Biomed Ltd. dividends
L&K Biomed Ltd. has not paid dividends in the last 6 fiscal years.
Last stock split: 1.5:1 on Oct 6, 2014.
Who owns L&K Biomed Ltd.
- Insiders 12.01%
- Institutions 0.32%
- Public & others 87.68%
- Shares outstanding 22.4M
- Free float 19.7M
L&K Biomed Ltd. company profile
- Company name
- L&K Biomed Ltd.
- Ticker
- 156100.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 105
- Fiscal year end
- December
- Address
- 16-25, Dongbaekjungang-ro 16beon-gil, Yongin-si, South Korea, 17015
- Phone
- 82 2 1600 0841
- Website
- lnkbiomed.com
About L&K Biomed Ltd.
L&K Biomed Ltd., engages in the manufacturing, production, and sales of medical devices in South Korea, the United States, Thailand, and internationally. The company offers spinal products comprising BlueEX-T, BluEX-TC, BluEX-A, BlueEX-L, and BluEX-ATP; BluEX-LT, an advanced lateral cage system for spinal lordosis restoration; PathLoc-TM, an expandable TLIF/PLIF lumbar cage system; AccelFix-XL, an expandable lateral lumbar cage system; AccelFix-XTP, an expandable lumbar cage system for anterior-to-psoas approach; and PathLoc-TA, an expandable ALIF anterior lumbar cage system. It also provides CastleLoc-C, an anterior cervical interbody fusion cage; CastleLoc-P, an anterior cervical plate system; CastleLoc-S, a posterior cervical fixation system; BluEX-C, a cervical expandable cage; AccelFix-S, a lumbar spinal fixation screw system; AccelFix-LP, a lumbar plate system; OpenLoc-L, a lumbar spinal fixation system; LnK Lumbar Peek Cages for posterior lumbar interbody fusion procedures; PathLoc-L, a MIS spinal system; AccelFix-MIS, a spinal fixation system; and PathLoc-SI sacroiliac fixation and fusion system that offers fusion and stabilization of the SI joint. In addition, the company offers CastleLoc Pectus bar system for the correction of pectus excavatum. L&K Biomed Ltd. was founded in 2008 and is headquartered in Yongin-si, South Korea.
L&K Biomed Ltd. management
2- Mr. Guk-jin KangCEO & Director · born 1966
- Mr. Kang Kuk NamExecutive Director · born 1975